Official Title
Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial
Brief Summary

Around 30% of admitted patients with COVID-19 pneumonia develop a hyper-inflammatory state whose progression to an acute respiratory distress syndrome (ARSD) could be prevented by the early initiation of immune-modulatory agents. The role of glucocorticoids (GC) in this setting remains controversial. This study aims to assess the safety and effectiveness of GC pulses to improve the clinical outcomes of patients with COVID-19 pneumonia with risen inflammatory biomarkers.

Completed
COVID-19 Pneumonia

Drug: Methylprednisolone

-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión

Other: Placebo

-An infusion bag of 100 mL of 0.9% saline

Eligibility Criteria

Inclusion Criteria:

- Age ≥18 years old.

- Diagnosis of SARS-CoV-2 pneumonia confirmed by reverse transcriptase polymerase chain
reaction (RT-PCR) on nasopharyngeal swab or sputum according to the recommendations of
the Spanish Ministry of Health.

- Length of symptoms consistent with COVID-19 ≥7 days.

- Hospital admission.

- At least one of the following: CRP >60 mg/L, IL-6 >40 pg/mL, ferritin >1000 μg/L.

- Acceptation of informed consent

Exclusion Criteria:

- Allergy or contraindication to any of the drugs under study.

- SpO2 <90% (in air ambient) or PaO2 <60 mmHg (in ambient air) or PaO2/FiO2 <300 mmHg.

- Ongoing treatment with glucocorticoids, immunosuppressive, or biologic drugs with
another indication.

- Decompensated diabetes mellitus.

- Uncontrolled hypertension.

- Psychotic or manic disorder.

- Active cancer.

- Pregnancy or lactation.

- Clinical or biochemical suspicion (procalcitonin >0.5 ng/mL) of active infection other
than SARS-CoV-2.

- Out-of-hospital management patient.

- Conservative or palliative management patient.

- Participation in another clinical trial.

- Any important and uncontrolled medical, psychological, psychiatric, geographic or
social problem that contraindicates the patient's participation in the trial or that
does not allow adequate follow-up and adherence to the protocol and evaluation of the
study results.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 75 Years
Countries
Spain
Locations

Hospital Sant Joan Despí Moisès Broggi
Sant Joan Despí, Barcelona, Spain

Complejo Hospitalario de Navarra
Pamplona, Navarra, Spain

Iñigo Les Bujanda, PhD, Principal Investigator
Complejo Hospitalario de Navarra

Fundacion Miguel Servet
NCT Number
Keywords
Covid-19
Pneumonia
Inflammatory phase
Glucocorticoids
MeSH Terms
COVID-19
Pneumonia
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate